Key Highlights

  • Preclinical data show synthetic lethality from GLIX1 plus olaparib combination
  • Patient-derived xenograft model used to test HR-proficient ovarian cancer
  • Low-dose combination matched cisplatin-level tumor shrinkage
  • Combination overcame resistance typical of PARP inhibitor monotherapy
  • Shares fell 5% to $2.96 despite the encouraging findings

BioLineRx Ltd. and its partner Hemispherian AS disclosed preclinical findings this week pointing to a potent therapeutic synergy between GLIX1, Hemispherian's novel oral TET2 activator, and olaparib, a widely used PARP inhibitor. The companies tested the combination in a patient-derived xenograft model of HR-proficient ovarian cancer — a subset of the disease that typically responds poorly to PARP inhibitors alone, since these tumors retain functional homologous recombination DNA repair machinery that allows cancer cells to circumvent the drugs' intended mechanism.

The results suggested the GLIX1-olaparib pairing may sidestep that resistance problem. According to the companies, the combination successfully triggered synthetic lethality — a therapeutic effect in which two otherwise survivable cellular deficiencies become lethal in combination — even in tumors that would ordinarily evade PARP inhibitor monotherapy. Notably, the low-dosage regimen achieved tumor shrinkage comparable to standard cisplatin chemotherapy while outperforming olaparib used alone, a result that, if replicated in later-stage studies, could expand the addressable population for PARP inhibitor-based regimens well beyond the BRCA-mutated tumors where they are currently most effective.

Despite the scientific promise, BioLineRx shares closed down 5% at $2.96, a reminder that preclinical data — however compelling — still carries substantial translational risk before it can influence clinical outcomes or valuation in a durable way. Xenograft models, while informative, do not always predict human efficacy, and the path from a patient-derived mouse model to a validated clinical regimen typically spans years and multiple additional data readouts.

Still, the companies are moving to capitalize on the finding. BioLineRx and Hemispherian intend to integrate an ovarian cancer cohort into their existing Phase 1/2a expansion study, positioning the combination for real-world testing in patients whose tumors have proven resistant to platinum-based chemotherapy — a population with limited remaining treatment options and correspondingly high unmet medical need.

What did the BioLineRx-Hemispherian preclinical data show?

The GLIX1-olaparib combination triggered synthetic lethality in HR-proficient ovarian cancer xenograft models, achieving cisplatin-comparable tumor shrinkage while overcoming resistance typically seen with PARP inhibitor monotherapy.

What are the next steps for the GLIX1-olaparib program?

BioLineRx and Hemispherian plan to add an ovarian cancer cohort to their ongoing Phase 1/2a expansion study, targeting platinum-resistant gynecologic cancer patients.

This article is for informational purposes and does not constitute investment advice.